incretin hormone is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
Quality control relies on pharmacopoeial monographs where they exist, combined with in-house specifications for identity, purity, water content, and counter-ion composition. Reference standards allow calibration across laboratories, although certified materials for every analogue are not universally obtainable. Batch records, chromatograms, and mass spectra form the documentation trail. Regulatory classification varies by jurisdiction and intended use, and research-grade material differs from pharmaceutical-grade material in testing scope. Analytical uncertainty is often expressed as relative standard deviation across replicate injections.
Lyophilised semaglutide is generally held at -20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept at 2-8 °C and used within a defined window because degradation accumulates over time. Repeated freeze-thaw cycles are discouraged, since each cycle can promote aggregation and reduce monomeric content. Room-temperature stability of the solid has been examined in some studies but remains incompletely characterised for long durations, so cold storage is the conservative default for research material.
Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.
Snake venom toxicity is assessed by a toxicological test called the median lethal dose, lethal dose 50% (abbreviated as LD50), which determines the concentration of a toxin required to kill half the members of a tested population. The potency of wild snake venom varies considerably because of assorted influences such as biophysical environment, physiological status, ecological variables, genetic variation (either adaptive or incidental), and other molecular and ecological evolutionary factors. This is true even for members of one species. Such variation is smaller in captive populations in laboratory settings, though it cannot be eliminated. However, studies to determine snake venom potency must be designed to minimize variability. Several techniques have been designed to this end. One approach is to use 0.1% bovine serum albumin (also known as "fraction V" in Cohn process) as a diluent in determining LD50 values. It results in more accurate and consistent LD50 determinations than using 0.1% saline as a diluent. For example, fraction V produces about 95% purified albumin (dried crude venom). Saline as a diluent consistently produces widely varying LD50 results for nearly all venomous snakes. It produces unpredictable variation in precipitate purity (35-60%). Fraction V is structurally stable because it has seventeen disulfide bonds; it's unique in that it has the highest solubility and lowest isoelectric point of major plasma proteins. This makes it the final fraction to be precipitated from its solution. Bovine serum albumin is located in fraction V.
== Legacy == Robert Swanson's legacy can still be found to this day through the company he cofounded and led. Genentech continues to develop and produce therapeutic drugs, and some of his policies, such as allowing company scientists to publish, are still in place. Genentech scored many firsts under Swanson's leadership, such as developing the first drug produced via genetic engineering, being the first biotechnology company to go public, and being the first biotechnology company to sell its own drug. These accomplishments have earned Genentech, and Swanson, a place in the history of the biotechnology industry.
Topilutamide, known more commonly as fluridil and sold under the brand name Eucapil, is an antiandrogen medication which is used in the treatment of pattern hair loss in men and women. It is used as a topical medication and is applied to the scalp. Topilutamide belongs to a class of molecules known as perfluoroacylamido-arylpropanamides. Topilutamide is a nonsteroidal antiandrogen (NSAA), or an antagonist of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT). Topilutamide was introduced for medical use in 2003. It is marketed only in the Czech Republic and Slovakia. The patent for Topilutamide expired in 2020.
Sources: en.wikipedia.org
In medicine, treatment that experts agree is appropriate, accepted, and widely used. Health care providers are obligated to provide patients with the best practice. Also called standard therapy or standard of care. (NCI) Bias
The DNA encoding a fusion of coat protein and protein of interest is often encoded on a phagemid - a plasmid containing both a bacterial origin of replication and phage attachment sequence. This allows it to be maintained and amplified in bacteria without producing phage virons. When bacterial colony reaches a desired size, a helper plasmid is transformed into the bacteria to supply them with the rest of the phage genome, enabling viron production. Alternatively, these phage genes can maintained within bacteria under inducible promoters, obviating the need for separate helper plasmid introduction.
alkane Also paraffin. Any fully saturated acyclic hydrocarbon,An acyclic saturated hydrocarbon containing only carbon and hydrogen atoms with only single carbon–carbon bonds; alkanes generally have the formula CnH2n+2. i.e. one in which all carbon–carbon bonds are single bonds.
For Public Service. Virginia Dorothy Pitchers. For services to the community in Upton with Fishley, Norfolk. Lesley Porter. Principal's Personal Assistant, Oakgrove Integrated College, Derry-Londonderry. For services to Reconciliation in Northern Ireland. Elizabeth Shirley Powell. For services to the community in Brooke, Norfolk (to be dated 28th November 2023). Joan Prescott. For services to Young People and to the community in Melling, Merseyside. Derek Mark Preston. For services to the Northern Ireland Prison Service and to Charity in Northern Ireland. Kathleen Mary Prideaux. For services to the community in Allerford, Somerset. Herbert Proctor. For services to the community in Audley, Staffordshire. Margaret Douglas Rae. Lately President, Renfrewshire Girlguiding. For services to Girlguiding in Scotland. Mahbubur Rahman. For services to Charity and to the community in Oldham, Greater Manchester. Rehana Khanam Rahman. For services to the Bangladeshi Community. Helen Bridget Margaret Rayfield. Chair, Haringey Rhinos Rugby Football Club. For services to Rugby Union Football and to the community in the London Borough of Haringey. Alexander Ritchie. Trustee, New Deer Community Association and Founder Member, Buchan Heritage Society. For voluntary services to Cultural Heritage and to the community in North East Scotland. Patricia Christine Roberts. Lately Assistant District Commissioner, North Kent Cubs. For services to Young People in Kent. Jean Elna Roberts-Jones. For services to the community in Eastleigh and Fareham, Hampshire during Covid-19. Paul Rushworth.
Sources: en.wikipedia.org
== Biosynthesis == Nonribosomal peptides are synthesized by one or more specialized nonribosomal peptide-synthetase (NRPS) enzymes. The NRPS genes for a certain peptide are usually organized in one operon in bacteria and in gene clusters in eukaryotes. However, the first fungal NRP discovered, ciclosporin, is synthesized by a single 1.6MDa NRPS. The enzymes are organized in modules that are responsible for the introduction of one additional amino acid. Each module consists of several domains with defined functions, separated by short spacer regions of about 15 amino acids. The biosynthesis of nonribosomal peptides shares characteristics with the polyketide and fatty acid biosynthesis. Due to these structural and mechanistic similarities, some nonribosomal peptide synthetases contain polyketide synthase modules for the insertion of acetate or propionate-derived subunits into the peptide chain. The huge NRPSs containing several modules are called "type I". Those existing as separate enzymes (as well as a separate peptidyl carrier protein) are called "type II". As many as 10% of bacterial NRPS are type II. Some (type I) NRPS modules deviate from the standard domain structure, and some extra domains have been described. There are also NRPS enzymes that serve as a scaffold for other modifications to the substrate to incorporate unusual amino acids.
== Side effects == Very common (incidence > 10%) adverse effects include constipation, dry mouth, and drowsiness at the beginning of treatment. Common (1% < incidence ≤ 10%) adverse effects include drowsiness during maintenance therapy, tremor, headache, dizziness, vertigo, and weakness. Uncommon (0.1% < incidence ≤ 1%) adverse effects include weight gain.
== See also == Astronomical chronology Age of Earth Age of the universe Chronological dating, archaeological chronology Absolute dating Relative dating Phase (archaeology) Archaeological association Geochronology Closure temperature Geologic time scale Geological history of Earth Thermochronology List of geochronologic names General Consilience, evidence from independent, unrelated sources can "converge" on strong conclusions
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
Lower temperatures slow hydrolysis, oxidation and aggregation reactions that degrade the molecule over time. Lyophilised powder is more tolerant than solution, but both benefit from controlled conditions.